ResMed (NYSE:RMD) disclosed that a Phase III trial testing 1 of its sleep apnea devices on patients with symptomatic chronic heart failure didn’t meet primary endpoints and actually increased the risk of death.
Respiratory
Euronext suspends Carmat shares after artificial heart patient dies
Embracing the future of pediatric quality measurement
ABT unveils OTC glucose meter | Regulatory news for the week of April 20, 2015
Cardiac Assist wins CE Mark for emergency cannula
CardiacAssist last week said it nailed down CE Mark approval in the European Union for a cannula designed to both drain and re-infuse blood during life support procedures.
Embracing the future of pediatric quality measurement
CRM: BSX’s gain is STJ’s loss | Medtech Wall Street news for the week of March 23, 2015
Report: Becton Dickinson to shed assets after CareFusion buy
Olympus faces another superbug lawsuit
Distributor 3B Medical levels anti-trust lawsuit against ResMed
FDA releases February 2015 510(k) clearances
February 2015 510(k) Clearances
510(k) summaries or 510(k) statements for final decisions rendered during the period February 2015.
TOTAL 510(k)s THIS PERIOD 208
TOTAL WITH SUMMARIES 193
TOTAL WITH STATEMENTS 15
February 2015 510(k) Clearances